<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8272">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01961804</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC 2012-02</org_study_id>
    <nct_id>NCT01961804</nct_id>
  </id_info>
  <brief_title>PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma</brief_title>
  <acronym>PREVACT</acronym>
  <official_title>Phase 3 Study Comparing Preventive Reversal of Vitamine K Antagonist Versus Reversion Only in Case of Intracranial Bleeding in Patients Receiving Vitamine K Antagonist Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The occurence of a minor craniocerebral trauma in patients receiving vitamine K antagonist
      treatment leads to a high risk of bleeding.

      Current guidelines recommend to perform a CT scan, and, in case of intracranial bleeding, to
      reverse anticoagulation with concomitant administration of prothrombin complex concentrates
      (PCCs) and vitamin K.

      However, even if a reversion is performed, the prognostic of post-traumatic intracranial
      bleeding remain bad.

      The investigators hypothesize that, for patients admitted in an emergency department after a
      minor head trauma and receiving anticoagulant treatment, a systematic preventive reversion
      with PCCs can lead to a significant reduction of intracranial haemorrhage and can also
      improve the neurological prognostic of patients versus the current strategy.

      PREVACT will test this hypothesis, in an open label, randomized, multicentre, clinical trial
      involving 400 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of intracranial bleeding diagnosed in CT scan</measure>
    <time_frame>H20 +/- 4 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This primary outcome measure will be analyse in a centralised place by two neuro-radiologist in blind of the randomised group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volumetric measure of intracranial haemorrhage</measure>
    <time_frame>CT scan performed 20h+/-4 after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This secondary outcome measure will be analyse in a centralised place by two neuro-radiologist in blind of the randomised group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient having a decrease in their autonomy</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A loss of at least one point in the Glasgow Outcome Score Extended</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient having a systemic or neurologic ischemic attacks</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coagulation; Intravascular</condition>
  <condition>Craniocerebral Trauma</condition>
  <condition>Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Actual recommendations</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Current guidelines recommend to perform a CT scan and realise the anticoagulation reversion only in case of intracranial bleeding diagnosed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preventive reversion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Realise a preventive reversion before performing any CT scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Reversion</intervention_name>
    <arm_group_label>Actual recommendations</arm_group_label>
    <arm_group_label>Preventive reversion</arm_group_label>
    <other_name>Administration of prothrombin complex concentrates: KANOKAD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission in an emergency departement for a recent and isolated minor head trauma
             with at least one of the following characteristic : a period of alteration in the
             level of consciousness, a period of loss of consciousness (&lt; 30 min), a posttraumatic
             amnesia &lt; 24h, or any other neurological sign such a convulsion or a localised
             neurological sign

          -  Subject receiving anticoagulant treatment with anti-vitamin K for the treatment of
             atrial fibrillation (AF)

          -  Initial ED Glasgow Coma Scale (GCS) score of ≥13

          -  Achievable follow up

          -  Informed consent form signed by the patient or if he/she isn't able an emergency
             inclusion can be realised.

        Exclusion Criteria:

          -  Delay between the minor head trauma and the possible preventive PCC's administration
             &gt; 6h

          -  Subject receiving anticoagulant treatment other than anti vitamin K (heparin,
             fondaparinux, dabigatran, rivaroxaban, apixaban...)

          -  Subject receiving anticoagulant treatment for other reason than a AF

          -  Subject on antiplatelet treatment (except the use of low dose of aspirin (≤ 100
             mg/day)

          -  Delocalised biology INR in capillary blood &lt; 1.5 if it's available (only in
             departement where this analyse is a usual practice)

          -  Haemorrhage or suspected haemorrhage other than intracranial which could led to a
             reversion of the anticoagulation

          -  Head trauma associated with one or further potential haemorrhagic traumatic lesions

          -  Subject who reject the use of products derived from human blood

          -  Women who are pregnant

          -  Subject with any condition that, as judged by the investigator, would place the
             subject at increased risk of harm if he/she participated in the study

          -  Subject unable to provide written informed consent or not eligible to an emergency
             inclusion

          -  Subject without social security registered
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ROY Pierre-Marie, Professor</last_name>
    <phone>+33(2)-41-35-79-47</phone>
    <email>prevact@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>TAZAROURTE Karim, Physiciens</last_name>
    <phone>+33(2)-41-35-79-47</phone>
    <email>prevact@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Agen</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>TRINH DUC Albert, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROY Pierre Marie, PhD</last_name>
      <phone>+33 2 41 35 37 15</phone>
      <email>pmroy@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>GABLE Béatrice</last_name>
      <phone>+33 2 41 35 79 47</phone>
      <email>begable@chu-angers.fr</email>
    </contact_backup>
    <investigator>
      <last_name>ROY Pierre Marie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Beaumont sur Oise</name>
      <address>
        <city>Beaumont Sur Oise</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>RICARD-HIBON Agnès, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Chateauroux</name>
      <address>
        <city>Chateauroux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>LECLERC Maence, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>SCHMIDT Jeannot, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>HONNARD Didier, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>CARPENTIER Françoise, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHG du Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>CHOUKROUN Jacques, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH MELUN</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>TAZAROURTE Karim, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU METZ</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>BRAUN François, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chg Montauban</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>BERTRAND Lionel, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>LECONTE Philippe, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>HAUSFATER Pierre, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>RAY Patrick, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Avicenne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>ADNET Frédéric, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>LARDEUR Jean Yves, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>JOLY Luc Marie, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint Brieuc</name>
      <address>
        <city>Saint Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HOMAOUN ALIPOUR, MD</last_name>
    </contact>
    <investigator>
      <last_name>ALIPOUR Homauon, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Saint Malo</name>
      <address>
        <city>Saint Malo</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VERLEY Laurent, MD</last_name>
    </contact>
    <investigator>
      <last_name>VERLEY Laurent, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>DEHOURS Emilie, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>GABTENI Majhoub, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Craniocerebral Trauma</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin E</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
